These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 8263548)

  • 21. Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity by the novel selective dopamine D3-receptor partial agonist FAUC 329 predominantly in the nucleus accumbens of mice.
    Boeckler F; Leng A; Mura A; Bettinetti L; Feldon J; Gmeiner P; Ferger B
    Biochem Pharmacol; 2003 Sep; 66(6):1025-32. PubMed ID: 12963489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment.
    Fillebeen C; Mitchell V; Dexter D; Benaissa M; Beauvillain J; Spik G; Pierce A
    Brain Res Mol Brain Res; 1999 Oct; 72(2):183-94. PubMed ID: 10529477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice.
    Dluzen DE; McDermott JL; Liu B
    Neurotoxicol Teratol; 1996; 18(5):603-6. PubMed ID: 8888025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interference of 3-O-methyldopa with L-dopa treatment for MPTP-induced parkinsonism in mice.
    Fujitake J; Kuno S; Mizuta E
    Adv Neurol; 1990; 53():225-9. PubMed ID: 2239462
    [No Abstract]   [Full Text] [Related]  

  • 25. Short-term manganese pretreatment partially protects against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.
    Rojas P; Ríos C
    Neurochem Res; 1995 Oct; 20(10):1217-23. PubMed ID: 8746808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mouse brain by piroheptine and trihexyphenidyl.
    Saitoh T
    J Neurol Sci; 1988 Feb; 83(2-3):161-6. PubMed ID: 3258627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of co-administration of anticonvulsant and putative anticonvulsive agents and sub/suprathreshold doses of L-dopa upon motor behaviour of MPTP-treated mice.
    Fredriksson A; Palomo T; Archer T
    J Neural Transm (Vienna); 1999; 106(9-10):889-909. PubMed ID: 10599871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation by D2 dopamine receptors of in vivo dopamine synthesis in striata of rats and mice with experimental parkinsonism.
    Richard MG; Bennett JP
    Exp Neurol; 1994 Sep; 129(1):57-63. PubMed ID: 7925842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter.
    Gainetdinov RR; Fumagalli F; Jones SR; Caron MG
    J Neurochem; 1997 Sep; 69(3):1322-5. PubMed ID: 9282960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The effect of prolyl-leucyl-glycine (MIF-1) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on dopamine levels of the striatum].
    Sheng JG
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1989 Aug; 22(4):213-5, 253. PubMed ID: 2575971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease.
    Sundström E; Fredriksson A; Archer T
    Brain Res; 1990 Oct; 528(2):181-8. PubMed ID: 2271921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time-course and dose-response study on the effects of chronic L-DOPA administration on striatal dopamine levels and dopamine transporter following MPTP toxicity.
    Fornai F; Battaglia G; Gesi M; Giorgi FS; Orzi F; Nicoletti F; Ruggieri S
    Brain Res; 2000 Dec; 887(1):110-7. PubMed ID: 11134595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism.
    Rozas G; López-Martín E; Guerra MJ; Labandeira-García JL
    J Neurosci Methods; 1998 Sep; 83(2):165-75. PubMed ID: 9765130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys.
    Doudet DJ; Chan GL; Holden JE; McGeer EG; Aigner TA; Wyatt RJ; Ruth TJ
    Synapse; 1998 Jul; 29(3):225-32. PubMed ID: 9635892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum.
    Ricaurte GA; Langston JW; DeLanney LE; Irwin I; Brooks JD
    Neurosci Lett; 1985 Sep; 59(3):259-64. PubMed ID: 3932903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunity of fetal mice to prenatal administration of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Melamed E; Rosenthal J; Youdim MB
    J Neurochem; 1990 Oct; 55(4):1427-31. PubMed ID: 2398363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'CH3-MPTP)-induced degeneration of mesostriatal dopaminergic neurons in the mouse: biochemical and neuroanatomical studies.
    Manaye KF; Sonsalla PK; Barnett G; Heikkila RE; Woodward DJ; Smith WK; German DC
    Brain Res; 1989 Jul; 491(2):307-15. PubMed ID: 2765888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Age-related susceptibility to MPTP-induced neurotoxicity in mice.
    Ali SF; David SN; Newport GD
    Neurotoxicology; 1993; 14(1):29-34. PubMed ID: 8361676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Recovery of nigrostriatal and mesolimbic dopaminergic system following administration of ganglioside in MPTP-treated mice].
    Date I; Asari S; Nishimoto A; Felten DL
    No To Shinkei; 1990 Nov; 42(11):1035-40. PubMed ID: 2076347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of testosterone upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system.
    Gao X; Dluzen DE
    Brain Res; 2001 Feb; 892(1):63-9. PubMed ID: 11172749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.